Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

The CRISPR gene editing technology has transformed the research lab, and this powerful tool is now making its way into the clinic. So far, three different human diseases have been successfully treated ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

This makes the organs virus-free and less likely to trigger an immune response, improving their safety and durability.

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...